Apixaban and CBD
Supplement–drug interaction evidence from the TruthStack database.
| Severity | HIGH |
|---|---|
| Evidence Tier | Moderate |
| Interaction Type | METABOLIC |
| Mechanism | METABOLISM |
| Last Reviewed | 2026-02-24 |
Summary
CBD inhibits CYP3A4 and P-glycoprotein, major apixaban elimination pathways. May significantly increase apixaban levels and bleeding risk.
CYP Enzyme Pathway Overlap
Apixaban and CBD share activity on the following CYP enzymes:
| Enzyme | Apixaban | CBD |
|---|---|---|
| CYP3A4 | SUBSTRATE (MODERATE) | INHIBITOR (STRONG) |
| P-gp | SUBSTRATE (MODERATE) | INHIBITOR (MODERATE) |
Shared Pharmacodynamic Endpoints
Both compounds influence the same physiological endpoints in the same direction:
| Endpoint | Direction | Apixaban | CBD |
|---|---|---|---|
| COAGULATION | DECREASE | STRONG | MODERATE |
Cumulative effect on shared endpoints may exceed individual compound profiles. This is relevant to discussion with a prescribing clinician.
API Reference
GET https://api.truthstack.co/v1/check?c1=Apixaban&c2=CBD
Open, unauthenticated. Returns JSON. Developer documentation
Sources
Primary: 28577860
Related Interactions
What this page is and is not. TruthStack is an informational reference database that describes published pharmacological findings. It does not provide medical advice, diagnosis, or treatment recommendations. The information on this page reflects flags in our database and should not replace consultation with a qualified healthcare provider. Always discuss supplement-drug combinations with your prescriber or pharmacist.